90
Participants
Start Date
May 16, 2025
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
TQB2210 Injection
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.
NOT_YET_RECRUITING
Cancer Hospital of Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Zhongshan Hospital Fudan University, Shanghai
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
NOT_YET_RECRUITING
Chongqing University Cancer Hospital, Chongqing
NOT_YET_RECRUITING
Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha
RECRUITING
The Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
ZhuJiang Hospital of Southern Medical University, Guangzhou
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY